EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, NRIX: Nurix Therapeutics Inc

17 Apr 26 12:18
LAST:

17.43

CHANGE:
 0.74		OPEN:
16.89		HIGH:
17.49		ASK:
0.00		VOLUME:
152.5K
CHG(%):
4.43		PREV:
16.69		LOW:
16.75		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
17 Apr 2616.8917.4916.7517.43152.5K
16 Apr 2617.0417.1316.5216.69888.1K
15 Apr 2616.5117.1116.3616.971.68M
14 Apr 2616.0216.7615.7816.301.28M
13 Apr 2616.1616.8015.9015.91981.0K
10 Apr 2616.3016.6216.0216.031.16M
09 Apr 2615.6016.5015.4716.241.19M
08 Apr 2616.5717.1915.5215.602.01M
07 Apr 2615.6716.5415.6016.351.74M
06 Apr 2615.7716.8815.4215.791.68M

PROFILE

Name:Nurix Therapeutics Inc
About:Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:1700 Owens Street, San Francisco, CA, United States, 94158
Website:https://www.nurixtx.com
CUSIP:67080M103
CIK:0001549595
ISIN:US67080M1036
FIGI:BBG00SDJ8M78

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-4.38 
Forward P/E:-5.26 
PEG Ratio:0.16 
Price to Sales:15.67 
Price to Book:3.01 
Profit Margin:-2.93 
Operating Margin:-11.58 
Return on Assets:-0.32 
Return on Equity:-0.65 
EPS Ratio:-3.05 
Revenue:83.69M 
Shares:103.41M 
Market Cap:1.802B 

TECHNICAL INDICATORS

MA5:16.664.6%
MA10:16.336.7%
MA20:15.6911.1%
MA50:15.7210.9%
MA100:17.042.3%
MA200:13.8925.5%
STO9:96.95 
STO14:97.96 
RSI14:73.80 
MTM14:2.76
ROC14:0.19 
ATR:0.96 
Week High:17.490.3%
Week Low:15.7810.5%
Month High:17.490.3%
Month Low:14.0125.5%
Year High:22.5029.1%
Year Low:8.20112.7%
Volatility:17.47